NO20065400L - Preparat for a hindre tilbakekomst av slag. - Google Patents

Preparat for a hindre tilbakekomst av slag.

Info

Publication number
NO20065400L
NO20065400L NO20065400A NO20065400A NO20065400L NO 20065400 L NO20065400 L NO 20065400L NO 20065400 A NO20065400 A NO 20065400A NO 20065400 A NO20065400 A NO 20065400A NO 20065400 L NO20065400 L NO 20065400L
Authority
NO
Norway
Prior art keywords
stroke
preparation
repetition
initiation
prevent recurrence
Prior art date
Application number
NO20065400A
Other languages
English (en)
Inventor
Yasushi Saito
Mitsuhiro Yokoyama
Hideki Origasa
Masunori Matsuzaki
Yuji Matsuzawa
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of NO20065400L publication Critical patent/NO20065400L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Et preparat er tilveiebrakt som er effektivt for forhindring av initiering og/eller gjentakelse av slag, som er forventet å være spesielt effektivt for forhindring av initiering og/eller gjentakelse av slag hos en hyperlipidemisk pasient som har vært behandlet med HMG-CoA-RI, eller spesielt gjentakelse av slag hos en pasient mer enn seks måneder etter initieringen av slag, dvs. et preparat for forhindring av initiering og/eller gjentakelse av slag, som inneholder etylikosapentat som dets effektive komponent.
NO20065400A 2006-02-07 2006-11-22 Preparat for a hindre tilbakekomst av slag. NO20065400L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006029954 2006-02-07
PCT/JP2006/314074 WO2007091338A1 (ja) 2006-02-07 2006-07-14 脳卒中再発予防用組成物

Publications (1)

Publication Number Publication Date
NO20065400L true NO20065400L (no) 2008-11-06

Family

ID=38334862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065400A NO20065400L (no) 2006-02-07 2006-11-22 Preparat for a hindre tilbakekomst av slag.

Country Status (9)

Country Link
US (4) US7498359B2 (no)
EP (2) EP1982710B1 (no)
KR (1) KR101336756B1 (no)
CN (3) CN103751781A (no)
BR (1) BRPI0621313A2 (no)
CA (2) CA2571462C (no)
ES (1) ES2448424T3 (no)
NO (1) NO20065400L (no)
WO (1) WO2007091338A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CA2570763C (en) * 2005-07-08 2011-08-23 Mochida Pharmaceutical Co., Ltd. Composition for preventing onset of cardiovascular events
CA2571462C (en) * 2006-02-07 2013-08-13 Mochida Pharmaceutical Co., Ltd. Composition for preventing recurrence of stroke
NZ600720A (en) * 2008-01-10 2012-12-21 Takeda Pharmaceutical A Seamless Capsule For A Liquid Pharmaceutical Composition
CA2724983A1 (en) * 2008-05-20 2009-11-26 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
PT2395991E (pt) * 2009-02-10 2013-09-03 Amarin Pharmaceuticals Ie Ltd Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia
EP3791880A1 (en) 2009-04-29 2021-03-17 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa
LT3278665T (lt) 2009-04-29 2020-12-10 Amarin Pharmaceuticals Ireland Limited Stabili farmacinė kompozicija ir jos panaudojimo būdai
ES2856959T3 (es) 2009-06-15 2021-09-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011047091A1 (en) * 2009-10-13 2011-04-21 Martek Biosciences Corporation Methods for treating traumatic brain injury
WO2011087981A2 (en) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
EP2542060B1 (en) * 2010-03-04 2019-10-02 Amarin Pharmaceuticals Ireland Limited Compositions for treating and/or preventing cardiovascular disease
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
WO2013172344A1 (ja) 2012-05-15 2013-11-21 持田製薬株式会社 高血中高感度ｃ反応性蛋白質患者の心血管疾患一次予防剤
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
DK3363433T3 (da) 2012-06-29 2021-03-08 Amarin Pharmaceuticals Ie Ltd Fremgangsmåder til reduktion af risikoen for en kardiovaskulær begivenhed i et individ i statinbehandling ved anvendelse af eicosapentaensyreetylester
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
CN103239440A (zh) * 2013-05-10 2013-08-14 南京医科大学 米格列奈在制备治疗缺血性脑卒中药物中的应用
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
PT4056176T (pt) 2018-09-24 2024-05-27 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de eventos cardiovasculares num indivíduo
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533073B (en) * 1997-03-03 2003-05-21 Chugai Pharmaceutical Co Ltd Therapeutic agents for peripheral vascular disease
CN1200369A (zh) * 1997-05-22 1998-12-02 无锡市迅达化学品厂 鱼油多烯不饱和脂肪酸脂的精馏提取方法
US20020055529A1 (en) * 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
GB0210212D0 (en) 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
EP1501493B1 (en) 2002-05-03 2009-10-07 Pronova BioPharma Norge AS Use of epa and dha in secondary prevention of strokes
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
CN1778296B (zh) * 2005-07-19 2010-04-14 淮北辉克药业有限公司 他汀类药物的长效制剂
CA2571462C (en) * 2006-02-07 2013-08-13 Mochida Pharmaceutical Co., Ltd. Composition for preventing recurrence of stroke

Also Published As

Publication number Publication date
ES2448424T3 (es) 2014-03-13
US20070185198A1 (en) 2007-08-09
EP1982710A1 (en) 2008-10-22
US20090105340A1 (en) 2009-04-23
US20100305205A1 (en) 2010-12-02
EP2526937A1 (en) 2012-11-28
US8258183B2 (en) 2012-09-04
KR20080094073A (ko) 2008-10-22
WO2007091338A1 (ja) 2007-08-16
CA2571462A1 (en) 2007-08-07
CN103751781A (zh) 2014-04-30
CN101365438A (zh) 2009-02-11
CA2802892A1 (en) 2007-08-07
US7498359B2 (en) 2009-03-03
CN102743755B (zh) 2015-01-14
US9233093B2 (en) 2016-01-12
KR101336756B1 (ko) 2013-12-04
CN102743755A (zh) 2012-10-24
US20120295976A1 (en) 2012-11-22
BRPI0621313A2 (pt) 2011-12-06
US7795308B2 (en) 2010-09-14
EP1982710B1 (en) 2013-12-18
CA2571462C (en) 2013-08-13
EP1982710A4 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
NO20065400L (no) Preparat for a hindre tilbakekomst av slag.
CL2007003176A1 (es) Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
MY148496A (en) Dpp iv inhibitor formulations
EA200870474A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
EA201101191A1 (ru) Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение
EP2448410A4 (en) TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
GT200800151A (es) Inhibidores de 11-beta-hsd1
AR070497A1 (es) Composicion detergente que comprende lipasa
MY148079A (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX338530B (es) Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
CL2011001757A1 (es) Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico.
CL2007003802A1 (es) Compuestos derivados de piperidina, inhibidores de la sintasa de acidos grasos; procedimiento de preparacion de dichos compuestos; y su uso para tratar la obesidad o el sobrepeso.
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
CL2013001471A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
DK2049513T3 (da) Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
CL2011000604A1 (es) Compuestos derivados de multiheteroarilo, inhibidores de h-pgds, composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias y alergicas.
UA96076C2 (en) Use of trans-clomiphene
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
EA201290373A1 (ru) Синергическая противовирусная композиция и ее применение
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
CL2007002329A1 (es) Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application